Urolithin A for Health & Longevity

Evidence Review created on 08/05/2026 using AI4L / Opus 5

Also known as: UA, Uro-A, Mitopure, 3,8-dihydroxyurolithin, 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one

Motivation

Urolithin A is not a nutrient found in food, and the body does not make it on its own. It appears when certain gut bacteria break down substances in pomegranates, walnuts, and some berries. Interest grew because laboratory work suggested it helps cells clear out worn-out energy-producing structures and replace them with fresh ones.

The compound was identified in human samples decades ago and long treated as an ordinary by-product of digestion. That changed when researchers reported that feeding it to animals improved muscle function and extended life in a simple laboratory organism. A complication surfaced alongside that work: only a minority of people carry the gut bacteria needed to produce meaningful amounts from food, which is why purified versions are now sold directly as supplements.

This review examines what the human evidence shows about taking urolithin A for general health and for slowing age-related decline. It covers the size and quality of the trials, who paid for them, the benefits and harms that have been measured, how the compound is dosed, and where the evidence remains thin.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Urolithin A

The article provides a structured technical overview covering the compound’s chemistry as a benzo-coumarin, its microbial origin from ellagitannins, and the mitophagy literature. It is useful as a fast orientation to nomenclature and chemical identity before reading the clinical literature.

Examine

Urolithin A

Examine’s dedicated page categorises urolithin A primarily under muscle gain and exercise, and links to individual study breakdowns including the negative findings in trained runners. Examine sells subscriptions rather than supplements, which limits but does not eliminate commercial incentive in how conclusions are framed.

ConsumerLab

Urolithin A For Age-Related Muscle Decline?

The most valuable part of this entry is its product-quality reporting: it tracks third-party test results showing widespread label inaccuracy and documents the 2026 U.S. federal court injunction barring nineteen companies from selling urolithin A supplements. ConsumerLab is a paid-subscription testing service that does not sell supplements, so most of the analytical detail sits behind a paywall.

Systematic Reviews

The following systematic reviews summarize the human and preclinical evidence base for urolithin A and related urolithins.

Targeting aging with urolithin A in humans: A systematic review - Kuerec et al., 2024

The only systematic review restricted to human urolithin A data, covering five studies and 250 healthy participants at 10–1,000 mg/day for 28 days to 4 months, it reports a dose-dependent anti-inflammatory effect, increased muscle strength and endurance, and upregulated mitochondrial and autophagy gene expression, but explicitly no effect on maximal adenosine triphosphate (ATP, the molecule cells use as their immediate energy currency) production, mitochondrial biogenesis, dynamics, or gut microbiota composition. An unresolved limitation is that most of the included trials were funded, designed, or co-authored by Amazentis SA, the Swiss company that manufactures the branded urolithin A ingredient Mitopure, which is the dominant conflict of interest running through this entire literature.
The Therapeutic Relevance of Urolithins, Intestinal Metabolites of Ellagitannin-Rich Food: A Systematic Review of In Vivo Studies - Tow et al., 2022

A review of 41 animal studies covering neuroprotective, metabolic, kidney, cardiac, anti-inflammatory and musculoskeletal effects of urolithins A and B. It is the best single map of which claimed benefits rest on animal data only, and it identifies the SIRT1 (sirtuin 1, a nutrient-sensing enzyme), AMPK (AMP-activated protein kinase, a cellular fuel-shortage sensor), and PI3K/AKT/mTOR (phosphoinositide 3-kinase and protein kinase B, two relay enzymes that carry growth and survival signals, feeding into the mechanistic target of rapamycin, a cellular growth-signalling hub) pathways as the proposed mediators.
Impact of nutraceuticals and dietary supplements on mitochondria modifications in healthy aging: a systematic review of randomized controlled trials - Lippi et al., 2022

This review places urolithin A alongside other mitochondria-targeting supplements evaluated in randomized controlled trials (RCTs, studies in which participants are assigned by chance to treatment or placebo) in healthy older adults. Its value is comparative: it shows that urolithin A is among the better-characterized compounds in this class while still resting on a small number of trials.
Unveiling the Anticancer Potential of Urolithin A in Colorectal Cancer: A Systematic Review - Francisco et al., 2026

A synthesis of 15 laboratory cell-culture studies reporting that urolithin A inhibits colorectal cancer cell proliferation, migration and invasion and induces cell-cycle arrest and programmed cell death. The authors are explicit that the entirely preclinical nature of the evidence and the heterogeneity of concentrations used prevent any extrapolation to people, which is the appropriate reading of every cancer-related urolithin A claim currently in circulation.

Mechanism of Action

Urolithin A is a gut microbial metabolite, not a plant compound. Foods rich in ellagitannins — pomegranate, walnuts, pecans, strawberries, raspberries and oak-aged wine — release ellagic acid during digestion. Specific gut bacteria, including Gordonibacter species and Ellagibacter isourolithinifaciens, then perform a stepwise removal of hydroxyl groups and open the lactone ring to yield urolithins M-5, M-6, C, and finally urolithin A.

The primary proposed mechanism is mitophagy — the selective quality-control process by which a cell tags a damaged mitochondrion, wraps it in a membrane, and digests it, then rebuilds capacity through mitochondrial biogenesis. Urolithin A engages the classical PINK1/Parkin route (two proteins that normally tag damaged mitochondria for disposal) — human muscle biopsies show more of the active, phosphorylated form of Parkin after supplementation — and it also acts through PINK1/Parkin-independent routes: it recruits AMPK signalling, upregulates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha, the master switch for building new mitochondria), and engages SIRT1. Work published in 2025–2026 adds a calcium-dependent route in which urolithin A alters communication between the endoplasmic reticulum and mitochondria, activating CAMK2D (a calcium-sensing signalling enzyme) and Nrf2 (the master switch that turns on the cell’s own antioxidant defences).

A second, independent mechanism is anti-inflammatory. Urolithin A suppresses NF-κB (nuclear factor kappa B, a master switch for inflammatory genes) and dampens the NLRP3 inflammasome (a protein complex that triggers inflammation). It is also a dietary antagonist of the AhR (aryl hydrocarbon receptor, a sensor that links dietary and environmental chemicals to immune and gut-barrier responses), and it has weak activity at estrogen receptors in cell-culture systems.

Competing mechanistic explanations exist and they matter. The mitophagy-centric account is the one advanced by the compound’s developers and is supported by increased mitophagy-related protein levels in human muscle biopsies. The competing account holds that urolithin A behaves like a conventional polyphenol metabolite — lowering inflammation and oxidative stress systemically — and that the muscle findings follow from reduced inflammation rather than from mitochondrial recycling. The strongest support for this alternative comes from the human data itself: in the muscle trials, maximal ATP production, mitochondrial biogenesis markers and mitochondrial dynamics did not improve, while inflammation markers consistently fell. The one exception is a biogenesis signal reported in CD8+ T cells (the immune cells that kill virus-infected and cancerous cells) in the 2025 immune trial, which has not been reproduced in muscle. If mitophagy were driving the benefit in people at the magnitude claimed, measurable gains in mitochondrial capacity would be expected and have not appeared.

Key pharmacological properties:

Absorption and half-life: Urolithin A is lipophilic and poorly water-soluble; absorption improves substantially when taken with a fat-containing meal. Free urolithin A is barely detectable in plasma; circulation is dominated by conjugated forms, whose reported terminal half-life is in the range of roughly 17–22 hours. This supports once-daily dosing.
Metabolism: Extensive phase II conjugation in the gut wall and liver — glucuronidation by UGT1A10, UGT1A9 and UGT1A8 (enzymes that attach glucuronic acid to make compounds water-soluble for excretion), and sulfation by SULT1A1 (an enzyme that attaches sulfate groups for the same purpose). Cytochrome P450 involvement, including CYP3A4 (the liver enzyme that breaks down roughly half of all prescription drugs), is minimal — a meaningful contrast with whole pomegranate juice, which does inhibit CYP3A4.
Selectivity: Urolithin A is not a selective ligand for a single receptor. It acts as a mitophagy inducer, an AhR antagonist, a weak estrogen-receptor modulator, and an inhibitor of several inflammatory enzymes. This promiscuity is a reason for caution in unstudied populations.
Tissue distribution: Conjugated urolithin A and its metabolites have been recovered from prostate, colon, and breast tissue in human sampling studies. Brain penetration is unresolved; a dedicated cerebrospinal fluid kinetics trial began enrolling only in 2026.

Historical Context & Evolution

Original context: Urolithins were first isolated in the 1980s and were regarded purely as terminal breakdown products of dietary ellagitannins — metabolic waste with no assigned function. They had no “intended use” in the pharmaceutical sense; they were a curiosity of polyphenol chemistry.
Identification in humans: A Spanish group at CEBAS-CSIC in Murcia characterized urolithins as the dominant human metabolites of pomegranate and walnut polyphenols in the mid-2000s, and later established that people fall into distinct producer categories. This body of work — independent of any supplement manufacturer — remains the foundation of the field and is summarized in García-Villalba et al., 2022.
The pivot to longevity: The turning point was Ryu et al., 2016 in Nature Medicine, from Johan Auwerx’s laboratory at EPFL, reporting that urolithin A induced mitophagy, extended lifespan in the nematode Caenorhabditis elegans by roughly 45%, and improved muscle function in aged rodents. This reframed a digestive by-product as a candidate geroprotective compound and drove the commercial development of Mitopure by Amazentis SA, the EPFL spin-out founded by Chris Rinsch and Patrick Aebischer.
What the findings actually were, not only how they were received: The 2016 rodent work reported improved running endurance and grip strength in aged mice, with concurrent increases in mitophagy markers. The 2019 first-in-human study, Andreux et al., 2019, established safety across single doses to 2,000 mg and four weeks of daily dosing, and reported modulation of plasma acylcarnitines (fat-transport molecules that accumulate when mitochondria handle fat poorly) plus changed mitochondrial gene expression in muscle at 500 mg and 1,000 mg. Notably, it did not demonstrate any functional benefit — that claim rested on later trials.
Regulatory and commercial evolution: The U.S. Food and Drug Administration issued a no-questions response to a Generally Recognized as Safe (GRAS) notice for synthetic urolithin A in 2018, and European authorities subsequently authorized it as a novel food for adults in supplement form. Commercial claims then outran the trial data: in 2025, following an advertising self-regulatory challenge in the United States, the manufacturer of the leading branded product agreed to modify several muscle-benefit claims. In July 2026, a U.S. federal court barred nineteen companies from making or selling urolithin A supplements.
How scientific opinion has moved, on both sides: The initial reception treated the mitophagy story as close to settled. Two developments have complicated it. Against the compound: the largest human trial missed its primary endpoint, a trial in trained runners found no performance benefit, and a small heart-failure trial found no cardiac benefit. In its favour: a 2025 immune-aging trial in Nature Aging produced the first independent-institution positive human findings outside muscle, and the safety record has held. Neither side of this exchange has produced the long-duration, hard-outcome trial that would settle the question, and the current balance of opinion should be read as provisional rather than final.

Expected Benefits

Benefits are graded by the strength of the human evidence supporting them, not by the plausibility of the mechanism. For a health- and longevity-focused reader who already trains and eats deliberately, the practical question is whether urolithin A adds anything on top of that baseline — and the honest answer differs sharply by outcome and by starting fitness.

High 🟩 🟩 🟩

Improved Muscle Endurance

The most reproducible functional finding is an increase in the number of contractions a muscle can perform before fatiguing. It has now been shown in older adults, in sedentary middle-aged adults, and in resistance-trained young men, using different muscle groups and different fatigue protocols. The proposed mechanism is improved mitochondrial quality control raising the fraction of fibers able to sustain oxidative work. The main caveat is that laboratory fatigue resistance has not consistently translated into improved walking distance or everyday physical function, which the human systematic review flags explicitly.

Magnitude: In adults aged 65–90 taking 1,000 mg/day, contractions to fatigue at two months rose by a mean of 95.3 in the first dorsal interosseus and 41.4 in the tibialis anterior, versus 11.6 and 5.7 on placebo (Liu et al., 2022). In resistance-trained men at 1,000 mg/day for eight weeks, repetitions to failure increased by 2.00 more than placebo (p = 0.011; p is the probability that a difference this large would arise by chance alone, with values below 0.05 conventionally treated as unlikely to be chance) (Zhao et al., 2024).

Improved Markers of Mitochondrial and Cellular Health

Across every human trial that measured them, urolithin A shifts a consistent panel of blood markers: acylcarnitines and ceramides fall, and muscle-biopsy levels of mitophagy-related and mitochondrial metabolism proteins rise. These are surrogate markers rather than outcomes, but their reproducibility across independent laboratories, doses and populations is the strongest single feature of this evidence base. The important qualifier is the negative counterpart: maximal ATP production, mitochondrial biogenesis and mitochondrial dynamics did not improve in the same trials, so the biochemical signature is not accompanied by measurable capacity gains.

Magnitude: Statistically significant reductions in multiple plasma acylcarnitine and ceramide species at 4 months at 500–1,000 mg/day, with significantly increased muscle mitophagy protein expression; maximal ATP production changed by 0.07 mM/s on urolithin A versus 0.06 mM/s on placebo, a non-significant difference (Liu et al., 2022; Andreux et al., 2019).

Medium 🟩 🟩

Increased Muscle Strength ⚠️ Conflicted

Strength results are genuinely split. The largest trial in middle-aged adults reported an approximately 12% gain in leg strength without any structured training, and a trial in trained men found significant gains in maximal isometric force. Against this, the same middle-aged trial missed its pre-specified primary endpoint of peak power output, and the trained-men trial found no significant change in one-repetition maximum (the heaviest load liftable once) for bench press or squat. The pattern suggests urolithin A may improve force production under sustained or isometric conditions more than peak explosive output. All of the positive strength trials were funded or co-authored by the ingredient manufacturer, Amazentis SA.

Magnitude: Roughly 12% improvement in hamstring peak torque during knee flexion over 4 months at 500 or 1,000 mg/day in adults aged 40–65, while quadriceps knee-extension torque did not change significantly (Singh et al., 2022); maximal voluntary isometric contraction (peak force against an immovable resistance) improved by 43.50 N·m more than placebo in trained men (p = 0.048), while one-repetition maximum changes were not significant (Zhao et al., 2024).

Reduced Systemic Inflammation

Reductions in C-reactive protein (CRP, a general marker of body-wide inflammation) have appeared in the middle-aged trial, the older-adult trial, and the resistance-training trial. Because chronic low-grade inflammation is a shared driver of muscle loss, vascular disease and cognitive decline, this is arguably the most longevity-relevant of the reproducible findings. Mechanistically it is attributed to NF-κB and inflammasome suppression rather than to mitophagy. The effect is modest and measured over weeks to months, and one trial recorded a within-group CRP rise from baseline in the treatment arm even while the between-group comparison favored urolithin A, which is unresolved.

Magnitude: CRP significantly reduced versus placebo at 4 months in two trials; in trained men, CRP fell 0.79 mg/L relative to placebo (p = 0.032) over 8 weeks (Zhao et al., 2024; Singh et al., 2022).

Remodeling of the Aging Immune System

A 2025 randomized trial run through Georg-Speyer-Haus and Goethe University Frankfurt — an academic group rather than the manufacturer, though with company co-authors — found that four weeks of urolithin A expanded naive-like, less exhausted CD8+ T cells and shifted them toward burning fat rather than sugar. It also increased mature natural killer cells (fast-acting immune cells) and improved bacterial uptake by monocytes. This is the first well-controlled human evidence for a benefit outside skeletal muscle, and the direction of change is opposite to what normally happens with age. It is a single 50-person, 28-day trial reporting cellular rather than clinical outcomes, and no infection or vaccination endpoints were measured.

Magnitude: Naive-like CD8+ cell treatment difference 0.50 percentage points (95% confidence interval — the range within which the true effect most likely falls — 0.16 to 0.83; p = 0.0437); CD8+ fat-oxidation capacity treatment difference 14.72 percentage points (95% confidence interval 6.46 to 22.99; p = 0.0061) at 1,000 mg/day (Denk et al., 2025).

Faster Recovery from Strenuous Exercise

In competitive distance runners at altitude, urolithin A did not improve race performance but reduced markers of muscle damage and how hard the training felt. Proteomic screening of muscle biopsies in the same trial showed upregulated mitochondrial pathways and downregulated inflammatory pathways, which fits the recovery interpretation. For a reader who trains hard and is limited by recovery rather than by peak capacity, this may be the most relevant benefit, and it is one where the trained-athlete data is actually stronger than the untrained data.

Magnitude: Total area under the curve for creatine kinase (an enzyme released when muscle fibers are damaged) was significantly lower after a 3,000 m time trial (p < 0.0001), and rating of perceived exertion (how hard the effort felt) was lower (p = 0.02), at 1,000 mg/day for 4 weeks (Whitfield et al., 2025).

Low 🟩

Improved Aerobic Capacity ⚠️ Conflicted

Three trials point in different directions. In sedentary middle-aged adults, peak oxygen uptake and six-minute walk distance improved to a degree the authors called clinically meaningful. In highly trained runners, the within-group rise in maximal oxygen uptake was larger on urolithin A than on placebo but the treatment-by-time interaction was not statistically significant, and the 3,000 m time trial did not improve. A small pilot in trained academy soccer players cuts the other way: over a six-week preseason it found a significant gain in intermittent running capacity and in jump height, so the aerobic signal is not confined to people starting from a low training base as the distance-runner data alone would suggest. The most defensible reading is that the aerobic effect is inconsistent, appears most reliably where mitochondrial quality is limiting, and is itself split within the trained-athlete literature between one null and one positive trial, both small.

Magnitude: Roughly 10–15% improvement in peak oxygen uptake in low-fitness middle-aged adults over 4 months; in trained runners, VO₂ max (the highest rate of oxygen the body can use during all-out effort) rose 5.4% on urolithin A versus 3.6% on placebo, interaction p = 0.138; in twenty academy soccer players, Yo-Yo Intermittent Recovery Test Level 1 distance (a shuttle-running test of repeated high-intensity effort) improved by 239 m more than placebo (p = 0.048) and countermovement jump height (a vertical jump from a standing dip, a standard test of leg power) by 3.33 cm more than placebo (p = 0.020) at 1,000 mg/day for 6 weeks (Singh et al., 2022; Whitfield et al., 2025; Monsalve Acevedo et al., 2025).

Favorable Shift in Blood Lipids ⚠️ Conflicted

The only trial to report a lipid benefit was a ten-person crossover study in heart failure patients, in which high-density lipoprotein cholesterol rose while every other lipid measure and every cardiac measure was unchanged. A single positive result among many null comparisons in a trial this small is exactly the pattern that chance produces, and no larger trial has looked for it. It is listed because it is the only cardiovascular signal in the human record, not because it is convincing.

Magnitude: High-density lipoprotein cholesterol increased 6.46 ± 2.33 mg/dL versus placebo (p = 0.026) at 500 mg twice daily for 4 weeks, with no change in low-density lipoprotein cholesterol, triglycerides, total cholesterol, or any echocardiographic measure (Jamialahmadi et al., 2024).

Speculative 🟨

Brain and Cognitive Aging

Urolithin A reduces amyloid-beta burden and improves cognitive deficits in mouse models of Alzheimer’s disease, and improves markers of brain aging in chemically aged rodents. No completed human trial has measured cognition as a primary endpoint, and it is not established that meaningful amounts of the compound cross the blood-brain barrier — a cerebrospinal fluid kinetics study only began in 2026. The basis for this item is mechanistic and animal data only.

Joint Cartilage Preservation

Cell and animal work reports that urolithin A protects cartilage-forming cells from inflammatory damage and slows cartilage degradation in induced osteoarthritis models. Independent consumer testing organizations have specifically flagged the gap between these preclinical results and the absence of any human osteoarthritis trial. No controlled human data exists; the basis is mechanistic and animal only.

Cancer Risk Modulation

Laboratory studies consistently show that urolithin A inhibits proliferation and induces programmed cell death in colorectal, prostate and breast cancer cell lines, and urolithins concentrate in colon and prostate tissue after ellagitannin intake. Reviews published in 2026 describe the role as context-dependent, noting that enhancing mitophagy can also help established tumor cells survive metabolic stress. Two human oncology trials are underway; until they report, this remains mechanistic speculation with a plausible harm direction as well as a benefit direction.

Lifespan Extension

The compound entered the longevity field because it extended nematode lifespan by roughly 45% and improved healthspan markers in aged rodents. No human study has measured any mortality or lifespan-adjacent hard outcome; maximal mitochondrial capacity has not moved in any trial that measured it, and the only positive biogenesis signal is confined to immune cells in a single 28-day trial. The basis is animal data only.

Metabolic and Glucose Regulation

Rodent work reports that urolithin A improves insulin sensitivity, lowers fasting glucose and reduces fat accumulation in the liver in diet-induced obesity models, attributed to the same mitophagy and inflammation-suppressing routes described above. No completed human trial has measured glucose handling as an endpoint, and the muscle and immune trials in middle-aged and older adults reported no metabolic outcomes. A 180-participant National Institute on Aging trial testing insulin secretion after an oral glucose load is the first study designed to answer this; until it reports, the basis is mechanistic and animal only.

Skin Aging

A manufacturer-run trial of a topical cosmetic containing urolithin A reported reductions in visible signs of facial skin aging, and mitophagy induction is plausible in skin fibroblasts. No peer-reviewed trial of oral urolithin A on skin outcomes has been published, and the topical route bypasses the pharmacokinetics that govern oral use. The basis is a single unpublished cosmetic study and mechanistic reasoning.

Protection of Kidney Function

Rodent work reports that urolithin A limits damage in models of acute and drug-induced kidney injury, attributed to the same mitophagy and inflammation-suppressing routes described above; the kidney is one of the organ systems mapped by the animal-study review of urolithins. Independent consumer testing organizations list kidney protection among the claims made for the compound while noting the absence of human trials. No controlled human renal outcome data exists; the basis is mechanistic and animal only.

Retinal and Macular Health

Preclinical work reports that urolithin A protects retinal pigment cells from oxidative and inflammatory injury and clears damaged mitochondria in models relevant to age-related macular degeneration (progressive loss of central vision with age). This has been raised in consumer-facing coverage as a possible use, but no human trial has measured any vision endpoint and no plasma-to-retina exposure data exists. The basis is cell and animal data only.

Benefit-Modifying Factors

Gut microbiome producer status (metabotype): This is the single largest modifier. Only about 12% of people have detectable urolithin A at baseline, and roughly 40% convert precursors after a pomegranate juice challenge; the rest are non-producers. Producers are distinguished by higher gut microbial diversity and a higher Firmicutes-to-Bacteroidetes ratio. Direct supplementation delivers more than six-fold higher exposure than pomegranate juice and removes this variable entirely, which is why it is the only reliable route for a non-producer.
Genetic polymorphisms in conjugating enzymes: Variants in UGT1A9, UGT1A10 and SULT1A1 alter how fast urolithin A is converted to its conjugated forms. Faster conjugators reach lower free-compound exposure for the same dose. These variants have not been formally tested against urolithin A outcomes, so this is a mechanistically grounded expectation rather than a demonstrated modifier. APOE4 carriers (a gene variant that raises Alzheimer’s disease risk and alters fat handling) are of interest for the brain-related claims but have not been studied.
Baseline biomarker levels: The clearest signals appear in people who start with elevated inflammation and elevated acylcarnitines. Participants entering trials with low CRP had less room to improve, and the benefit on inflammation markers was dose-dependent. Baseline mitochondrial function measured by magnetic resonance spectroscopy did not predict response in the older-adult trial.
Baseline fitness and training status: Effects are largest and most consistent in sedentary or low-fitness participants. In trained athletes the record is split: a trial in highly trained distance runners found recovery benefit without any performance gain, while a smaller pilot in academy soccer players found improved intermittent running capacity and jump height over a preseason block. For a reader who already trains seriously, recovery remains the better-documented benefit, and any performance gain should be treated as unsettled.
Sex-based differences: No trial has been powered to detect a sex interaction. The older-adult trial was 76% women, while the athlete and resistance-training trials were male-only, so the two strongest positive datasets come from non-overlapping sexes. Urolithin A has weak estrogen-receptor activity in cell culture, giving a theoretical basis for sex-dependent responses that remains untested.
Pre-existing health conditions: Chronic inflammatory conditions, sarcopenia (age-related loss of muscle mass and strength) and frailty are the states in which the largest theoretical benefit exists, and a dedicated frailty trial completed in 2025. Conversely, in heart failure with reduced ejection fraction (a weakened main pumping chamber), no functional benefit was found. Recent broad-spectrum antibiotic use abolishes food-derived urolithin production but does not affect direct supplementation.
Age-related considerations: Benefit magnitude tracks baseline decline. Adults in their sixties to eighties showed the clearest endurance gains; adults in their forties showed the clearest strength gains. There is no data in adults over 90, and the oldest trial participants were 90.

Potential Risks & Side Effects

For a proactive, risk-aware reader, the pharmacological risk profile of urolithin A is unusually benign and the product-integrity risk is unusually severe. That asymmetry is the central safety story here.

High 🟥 🟥 🟥

Mild Gastrointestinal Symptoms

Across every human trial, the most frequently reported adverse events have been mild-to-moderate gastrointestinal complaints: loose stools, nausea, bloating and abdominal discomfort. The likely mechanism is the poor water solubility of the compound and the osmotic and microbial effects of an unabsorbed fraction reaching the colon. In every controlled comparison, event rates were statistically indistinguishable from placebo, and events were judged unrelated or unlikely related to treatment. Severity has been uniformly low and symptoms resolve on discontinuation or with food.

Magnitude: No statistically significant difference in adverse event rates between urolithin A and placebo across trials at 500–1,000 mg/day for up to 4 months; all reported events mild or moderate, none serious (Liu et al., 2022; Andreux et al., 2019).

Medium 🟥 🟥

Widespread Product Adulteration and Underdosing

This is the most likely way a user is actually harmed — through wasted money and false confidence rather than toxicity. Independent laboratory analysis of commercially available urolithin A supplements found deviations from the label claim ranging from +28.6% to −100%, meaning some products contained none of the compound at all. A separate 2025 third-party testing program reported that roughly 60% of popular urolithin A products contained almost no urolithin A. In July 2026 a U.S. federal court barred nineteen companies from manufacturing, selling or distributing urolithin A supplements. Note that the study documenting label deviations comes from an academic longevity group with no supplement-manufacturing interest, whereas the most vocal amplifier of counterfeit concerns has been the dominant branded manufacturer, which has a direct commercial interest in that narrative.

Magnitude: Measured content deviating from label claim by +28.6% to −100% across tested products (Sandalova et al., 2024); approximately 60% of popular products found to contain almost no urolithin A in 2025 third-party testing.

Unknown Safety Beyond Four Months of Continuous Use

The longest published human exposure is four months, and the total published human safety experience is roughly 250–350 participants across all trials. For a compound taken indefinitely as a longevity intervention, this is a short observation window. Regulatory toxicology in rats is reassuring — no genotoxicity, no target organs identified, and a no-observed-adverse-effect level (the highest dose producing no detectable harm) at the highest dose tested — but rodent 90-day studies do not detect slow-developing effects in humans. No post-marketing pharmacovigilance system exists for supplements at the level applied to medicines.

Magnitude: Longest randomized exposure 4 months; rodent no-observed-adverse-effect level of 3,451 mg/kg body weight/day in males and 3,826 mg/kg/day in females over 90 days, roughly 200-fold above a 1,000 mg human dose on a body-weight basis (Heilman et al., 2017).

Low 🟥

Discordant Inflammatory and Antioxidant Marker Changes ⚠️ Conflicted

In the trial of resistance-trained men, urolithin A significantly lowered CRP relative to placebo but also raised CRP relative to the participants’ own baseline, and it significantly reduced superoxide dismutase (an antioxidant enzyme) relative to placebo. Reduced antioxidant enzyme activity can indicate less oxidative stress requiring defense, or it can indicate a blunted adaptive antioxidant response — the trial cannot distinguish these. With only twenty participants, the finding may be noise, but it is the one place in the literature where the inflammation story does not cleanly cohere.

Magnitude: CRP rose 0.71 ± 0.21 mg/L from baseline within the treatment arm (p = 0.001) while falling 0.79 ± 0.38 mg/L versus placebo (p = 0.032); superoxide dismutase fell 4.32 ± 0.90 U/mL versus placebo (p = 0.041) (Zhao et al., 2024).

Cost Without Demonstrated Hard-Outcome Benefit

At typical retail pricing, sustained use of a verified product runs several hundred to over a thousand US dollars per year, indefinitely, for surrogate-marker benefits and modest functional gains. No insurer or national health system reimburses it, and no institutional payer has any incentive to evaluate it — unlike prescription geroprotective candidates, there is no structural counterweight pushing for independent efficacy assessment. The financial risk is real and asymmetric: the manufacturer benefits from continued use regardless of individual response.

Magnitude: Approximately USD 1.50–3.00 per day for a verified branded product at trial-equivalent dosing, roughly USD 550–1,100 per year.

Speculative 🟨

Interference with Tumor Biology or Cancer Immunotherapy

Enhancing mitophagy is not unidirectionally protective. Reviews published in 2026 describe urolithin A’s role in cancer as context-dependent, since the same quality-control machinery that protects healthy cells can help established tumor cells survive metabolic and therapeutic stress. Its expansion of memory stem T cells is being explored as a way to improve response to checkpoint inhibitors (cancer drugs that release the brakes on the immune system so it can attack tumors), but the direction of effect in people with active cancer is unknown. No controlled human safety data exists in oncology populations; two trials are enrolling.

Estrogen-Receptor Activity in Hormone-Sensitive Conditions

Cell-culture work characterizes urolithin A as a selective estrogen-receptor modulator that also attenuates 27-hydroxycholesterol signalling in breast cancer cells. In that setting the effect appeared favorable, but any compound with estrogen-receptor activity carries theoretical risk in hormone-sensitive breast, endometrial or prostate disease, and in people on endocrine therapy. Circulating urolithin A exists almost entirely in conjugated form, which likely limits receptor engagement in vivo. The basis is in vitro data only.

Immune or Gut-Barrier Effects from Aryl Hydrocarbon Receptor Antagonism

Urolithin A is a dietary antagonist of the aryl hydrocarbon receptor, which regulates gut-resident immune cell populations and epithelial barrier maintenance. Chronic antagonism of this pathway has theoretical implications for mucosal immunity that have never been examined in a supplementation trial. Conversely, several animal studies report improved gut barrier integrity with urolithin A, so the net direction is unclear. The basis is mechanistic reasoning from isolated reports.

Competition for Phase II Conjugation Capacity

Because urolithin A is heavily glucuronidated and sulfated, gram-level daily dosing could in principle compete for the same enzymes that clear other compounds, including paracetamol, some hormones, and several drugs. No clinical interaction study has been performed. The theoretical concern is greatest in people with reduced liver reserve. The basis is mechanistic inference, not observed events.

Risk-Modifying Factors

Genetic polymorphisms: Reduced-function variants in UGT1A9, UGT1A10 or SULT1A1 would be expected to slow clearance and raise free-compound exposure at any given dose, and Gilbert’s syndrome (a common inherited condition of reduced bilirubin conjugation) plausibly falls in the same category. None of this has been measured against urolithin A adverse events. Because the observed toxicity margin is very wide, the practical significance of slower conjugation is likely small.
Baseline biomarker levels: Elevated liver enzymes or reduced kidney filtration at baseline shift the risk calculation, since urolithin A conjugates are hepatically formed and renally cleared. Trials that measured them found no change in liver enzymes or kidney parameters after 28 days, but they enrolled participants with normal baseline values, so the finding does not extend to impaired organs.
Sex-based differences: No sex-specific adverse event pattern has been reported, but the trials with the longest exposure were predominantly female while the athlete trials were exclusively male, so sex-stratified safety data barely exists. Estrogen-receptor activity in cell culture provides a theoretical basis for sex-dependent risk in hormone-sensitive tissue that remains untested.
Pre-existing health conditions: Moderate-to-severe liver impairment (Child-Pugh Class B or C, a clinical grading of liver disease severity) and advanced kidney disease reduce the body’s ability to conjugate and excrete the compound. Active hormone-sensitive cancer, active inflammatory bowel disease, and current cancer immunotherapy are settings where the compound’s non-selective activity has plausible but unmeasured consequences. Recent gastrointestinal surgery or malabsorption reduces the absorption of a lipophilic compound.
Age-related considerations: Adults in their seventies and eighties tolerated 1,000 mg/day for four months as well as younger participants, with no age-related excess of adverse events. However, the older the user, the more likely they are to take multiple medications and to have reduced hepatic and renal reserve, which raises the theoretical significance of unstudied conjugation competition. There is no data below age 18 or above age 90.

Key Interactions & Contraindications

No clinical drug-interaction study of purified urolithin A has been published. Everything below is derived from its known metabolic route and receptor activity, and should be read as anticipatory rather than documented.

Drugs cleared by glucuronidation (paracetamol/acetaminophen, morphine, lorazepam, mycophenolate, raltegravir): Caution. Gram-level urolithin A could compete for the same UGT enzymes, theoretically raising exposure to these drugs. Mitigation: timing separation of at least 4 hours, with high-dose paracetamol kept off the same schedule; no dose adjustment is established.
Drugs cleared by sulfation (paracetamol/acetaminophen, salbutamol, minoxidil): Caution, same reasoning via SULT1A1. Mitigation: timing separation.
UGT inhibitors (valproic acid, probenecid, mefenamic acid): Caution. These could slow urolithin A conjugation and raise free-compound exposure. Consequence is unlikely to be clinically important given the wide toxicity margin. Mitigation: none required beyond awareness.
Whole pomegranate juice and pomegranate extract: Caution — but for the opposite reason to the supplement. Pomegranate juice inhibits CYP3A4 and can raise levels of statins (cholesterol-lowering drugs; simvastatin, atorvastatin), calcium channel blockers (blood-pressure drugs that relax artery walls; amlodipine, nifedipine) and warfarin. Purified urolithin A does not carry this liability. Mitigation: for anyone taking CYP3A4-dependent drugs, high-dose pomegranate extract is not an equivalent substitute for purified urolithin A.
Broad-spectrum antibiotics (amoxicillin-clavulanate, ciprofloxacin, metronidazole): Monitor. These suppress the gut bacteria that convert dietary ellagitannins to urolithins, eliminating food-derived production for weeks. They do not affect a directly supplemented product — which is precisely the argument for supplementation over dietary strategies during and after antibiotic courses.
Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab): Caution pending data. Urolithin A alters CD8+ T cell differentiation, which is the mechanism these drugs depend on. The interaction could be synergistic or antagonistic; a dedicated trial is enrolling. Mitigation: confined to a clinical trial setting or to use known to the treating oncologist.
Endocrine therapy for hormone-sensitive cancer (tamoxifen, anastrozole, letrozole): Caution. Urolithin A shows estrogen-receptor modulating activity in cell culture, creating a theoretical possibility of interference. Mitigation: avoidance outside specialist supervision.
Over-the-counter medications: Caution for high-dose paracetamol/acetaminophen, which is the main one of concern for the conjugation reasons above; the theoretical consequence is raised paracetamol exposure. Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) have no known interaction, though both they and urolithin A lower inflammatory markers, so combined use confounds biomarker interpretation. Antacids and proton pump inhibitors (drugs that shut down stomach acid production; omeprazole, pantoprazole) rate as monitor only: they may modestly reduce absorption of a poorly soluble compound, with underexposure as the consequence. Mitigation: timing separation of 2 hours.
Supplements with additive mitophagy, autophagy or anti-inflammatory effects (spermidine, nicotinamide riboside, nicotinamide mononucleotide, resveratrol, fisetin, quercetin, curcumin, omega-3 fatty acids): Monitor. Additive rather than harmful in expectation, the practical consequence being uninterpretable biomarkers rather than toxicity, but no combination has been tested and additive inflammation-lowering makes it impossible to attribute a biomarker change to any one agent. Mitigation: sequential introduction of one agent at a time, with at least 8 weeks between additions.
Other interventions: Monitor. Resistance training is the most important co-intervention — every mechanism urolithin A engages overlaps with training adaptation, and no trial has tested whether the two are additive or redundant, so the consequence is an unquantifiable incremental effect rather than a hazard. Metformin and rapamycin act on overlapping fuel-sensing and growth-signalling pathways; combined use is untested, and caution is warranted until it is.
Populations who should avoid it: Pregnancy and lactation (no human data of any kind, and the compound crosses into breast milk in trace form). Anyone under 18 (no data). Child-Pugh Class B or C liver impairment. Chronic kidney disease stage 4 or 5 (estimated glomerular filtration rate, a calculated measure of kidney filtering speed, below 30 mL/min/1.73 m²). Active hormone-sensitive malignancy or current endocrine therapy, pending data. Anyone on active cancer immunotherapy outside a trial. Known hypersensitivity to ellagitannin-rich foods.

Risk Mitigation Strategies

Documented product verification: Independent testing has found up to 60% of products containing almost no active compound, so protocols in this category rest on material with a batch-specific certificate of analysis quantifying urolithin A by high-performance liquid chromatography (a standard laboratory method for quantifying a compound), or on a product carrying independent third-party certification. This mitigates the dominant practical risk in this category — paying for and drawing conclusions from an inert powder.
Low starting dose with stepped titration: Trial doses ranged from 250 mg to 1,000 mg daily, and the higher dose is where most functional benefits were seen; a common practical pattern is 250–500 mg daily for 2 weeks before moving to 1,000 mg, since starting low identifies gastrointestinal intolerance cheaply. This mitigates the loose stools, nausea and bloating that constitute the only consistently reported adverse events.
Dosing with a fat-containing meal: Urolithin A is lipophilic and poorly water-soluble, so a fasted dose both reduces absorption and increases the unabsorbed colonic fraction; protocols therefore pair the dose with a meal containing at least 10–15 g of fat. This mitigates gastrointestinal symptoms and underexposure simultaneously.
Baseline organ-function testing: Because the compound is heavily conjugated in the liver and cleared by the kidneys, and because trial safety data covers only people with normal baseline organ function, liver enzymes and kidney function measured before starting and repeated at 3 months establish whether an abnormality pre-existed. This mitigates the risk of attributing an incidental abnormality to the supplement, and of using it in unrecognized organ impairment.
Timing separation from conjugated drugs: Gram-level daily dosing plausibly competes for the same UGT and SULT enzymes as paracetamol/acetaminophen and other heavily conjugated drugs, so a gap of at least 4 hours is the standard precaution. This mitigates the speculative but mechanistically coherent risk of raising exposure to those drugs.
Exclusion of untested populations: There is no human data in pregnancy, lactation, active hormone-sensitive cancer, or cancer immunotherapy outside a trial, and the compound has estrogen-receptor and T-cell differentiation activity, which is why these settings sit outside every published protocol. This mitigates exposure of populations in whom a plausible harm mechanism exists and no counterbalancing evidence does.
Washout before unrelated blood work: Urolithin A lowers CRP and shifts acylcarnitines and ceramides, so a 2-week pause before any biomarker panel intended to assess something else keeps those markers interpretable. This mitigates misinterpretation of a cardiovascular or metabolic workup.
Pre-defined 4-month decision point: Trials ran 28 days to 4 months, and functional benefits emerged at 2–4 months. A decision rule fixed in advance — stopping if pre-defined markers and functional tests have not moved — mitigates the open-ended cost risk of indefinite use without individual evidence of response.
Larger-effect interventions first: Resistance training and adequate protein intake produce strength and endurance changes larger than anything reported for urolithin A. Establishing those before adding a supplement mitigates the risk of substituting it for the intervention it is meant to complement.

Therapeutic Protocol

Standard dose: 500 mg or 1,000 mg once daily. Both doses produced measurable biochemical effects in the first-in-human study; 1,000 mg is the dose used in the older-adult endurance trial, the immune trial, the athlete trial and the resistance-training trial, and is the dose behind most functional findings. 500 mg is the ceiling authorized for adult supplement use under European novel food rules.
Lower-dose alternative: 250 mg daily produced detectable plasma exposure and some gene-expression changes in the first-in-human study but no functional data supports it. It is reasonable only as a tolerance-building step.
Competing approach — dietary precursors instead of the purified compound: Consuming pomegranate juice, walnuts, pecans or ellagitannin-rich berries daily relies on the gut microbiome to produce urolithin A. This is the approach favored by researchers in the polyphenol field, notably the CEBAS-CSIC group in Murcia, who argue that the whole-food matrix delivers multiple bioactive metabolites rather than one. Its limitation is measured directly: only about 12% of people have detectable urolithin A at baseline, roughly 40% convert after a juice challenge, and direct supplementation gives more than six-fold higher exposure. Neither approach has been shown superior for a clinical outcome; they differ in reliability, cost, and breadth.
Competing approach — purified supplementation: Popularised by Amazentis SA and its Timeline consumer brand, developed out of Johan Auwerx’s laboratory at EPFL and Patrick Aebischer’s institutional support, and promoted in the clinical-longevity space by practitioners including Gabrielle Lyon. This is the approach on which essentially all the human functional data rests, and also the one with the direct commercial interest.
Best time of day: Morning with breakfast in most trial protocols. There is no circadian rationale in the human data; the practical argument for morning dosing is that it pairs the dose with a fat-containing meal and avoids adding a poorly soluble compound close to bedtime. A minority of practitioners suggest evening dosing to align mitophagy induction with the overnight fasting window, which is mechanistically speculative.
Half-life and dosing frequency: The circulating conjugated forms have a reported terminal half-life of roughly 17–22 hours, which supports once-daily dosing and predicts accumulation to steady state over 3–5 days. Free urolithin A itself is cleared far faster and is barely detectable in plasma.
Single versus split dosing: Trials have used both. The 1,000 mg trials mostly used a single daily dose; the heart failure trial used 500 mg twice daily. Splitting has a theoretical absorption advantage for a poorly soluble compound and reduces the unabsorbed colonic load that drives gastrointestinal symptoms, so 500 mg twice daily with meals is a reasonable choice for anyone with loose stools on a single dose.
Genetic polymorphisms influencing dose choice: Reduced-function UGT1A9, UGT1A10 or SULT1A1 variants, and Gilbert’s syndrome, would be expected to raise exposure at a given dose and argue for starting at 250–500 mg. Conversely, no genotype has been shown to require a higher dose. APOE4 status has no established bearing on dosing. None of this has been prospectively tested.
Sex-based differences in dosing: No trial has used sex-specific dosing, and the two strongest positive datasets came from a predominantly female older cohort and exclusively male athlete cohorts, both at 1,000 mg/day. There is no evidence-based reason to dose differently by sex.
Age-related considerations: Adults aged 65–90 used 1,000 mg/day for four months without dose adjustment and showed the clearest endurance gains. In adults over 80, and in those with reduced kidney or liver reserve, protocols commonly start at 500 mg, since conjugation and renal clearance both decline with age. Adults in their forties and fifties showed strength gains at 500 mg as well as 1,000 mg.
Baseline biomarker levels influencing response: Elevated CRP and elevated acylcarnitines at baseline mark the group with the most room to improve and the clearest documented response. A plasma or dried-blood-spot urolithin A measurement 6 hours after a dose confirms both that the product is genuine and that absorption is occurring.
Pre-existing conditions influencing response: Sarcopenia, frailty and chronic low-grade inflammation are the states in which benefit is most plausible. Heart failure with reduced ejection fraction showed no functional benefit at 500 mg twice daily. Malabsorptive conditions and recent bariatric surgery reduce absorption of a lipophilic compound and argue for split dosing with fat.
Co-intervention: Every trial that produced strength gains in untrained adults did so without structured training, and among trained people the results diverge — recovery benefit without performance gain in distance runners, but improved intermittent running capacity in a small preseason soccer pilot. The practical implication is that urolithin A is best treated as an adjunct to resistance training and adequate protein rather than an alternative to either.

Discontinuation & Cycling

Lifelong or short-term: Urolithin A is positioned commercially as an indefinite daily supplement, and the mechanism — continuous support of mitochondrial quality control — implies continuous use. The evidence does not support that framing beyond four months, because no trial has run longer. Functional benefits in the trials emerged between two and four months and were measured while dosing continued; nothing is known about persistence after stopping.
Withdrawal effects: None have been reported. Plasma conjugates clear within a few days of the last dose given a terminal half-life of roughly 17–22 hours, and no trial reported rebound in any measured marker on discontinuation. There is no physiological dependence mechanism.
Tapering: Not applicable. No trial tapered, no receptor downregulation or adaptive counter-regulation has been described, and stopping abruptly carries no known consequence.
Cycling for maintained efficacy: No trial has tested cycling, and no tolerance or diminishing response has been documented within a four-month window. The theoretical argument for cycling — that continuously elevated mitophagy signalling might suppress the cell’s own adaptive response, or blunt the mitochondrial stress signals that drive training adaptation — is speculative and untested. Some practitioners use 5-days-on/2-days-off or 3-months-on/1-month-off schedules on this reasoning; there is no data either supporting or refuting these schedules.
Practical stopping rule: Because the compound is expensive and its individual effect is invisible without measurement, a defined trial period is more informative than indefinite use. Establishing baseline inflammation markers and a repeatable functional test, dosing for four months, then reassessing, gives an individual answer where the population data is thin. A washout of 4 weeks is more than sufficient for any measured marker to return to baseline if a re-challenge is wanted.

Sourcing and Quality

Product integrity is the dominant issue in this category: Independent testing found label deviations from +28.6% to −100%, roughly 60% of popular products contained almost no urolithin A in 2025 third-party testing, and in July 2026 a U.S. federal court barred nineteen companies from making or selling urolithin A supplements. Nothing else about sourcing matters if the capsule is inert.
Form and synthesis route: Commercial urolithin A is chemically synthesized, not extracted from fruit — extraction is not economically viable at gram doses. The relevant quality question is therefore synthetic purity and residual solvent content, not botanical origin. Products marketed as “urolithin A” that list only pomegranate extract, punicalagin or ellagic acid on the ingredient panel do not contain urolithin A and rely on the buyer’s microbiome to make it.
Branded versus generic ingredient: Mitopure, made by Amazentis SA and sold under the Timeline brand, is the only urolithin A ingredient with both a U.S. Generally Recognized as Safe notification and European novel food authorization, and it is the material used in essentially every published trial. That is a genuine quality argument and also a commercial one made by an interested party; generic synthetic urolithin A of verified purity is chemically identical, and the branded premium buys traceability rather than a different molecule.
What to look for: A batch-specific certificate of analysis quantifying urolithin A by high-performance liquid chromatography; independent third-party certification such as NSF or United States Pharmacopeia verification; disclosed testing for heavy metals and residual solvents; a manufacturer that names its ingredient supplier. Liposomal or micronized formulations claim improved absorption of a poorly soluble compound, and bioavailability comparisons of several formulations have been run, but no formulation has been shown superior for a clinical outcome.
Where to avoid buying: Third-party marketplace listings have been the main vector for counterfeit and underdosed product, and were the subject of the 2026 injunction. Pharmacy, direct-from-manufacturer, or established supplement retailers with published test results substantially reduce this exposure.
Storage and stability: Urolithin A is a light- and oxidation-sensitive phenolic compound, so sealed, cool and dark storage within the stated expiry date is the standard handling condition; softgel formulations containing oil carriers are more prone to oxidative degradation than dry powder in capsules.
Verification by measurement: The most definitive check available to an individual is a plasma or dried-blood-spot urolithin A measurement taken about 6 hours after a dose. Programmes offering this exist, including one run by the ingredient manufacturer, which is worth noting as a commercial relationship even though the measurement itself is objective.

Practical Considerations

Time to effect: Plasma levels reach steady state within about a week, and gene-expression and biomarker changes appear within 28 days. Functional changes take longer: muscle endurance improvements were measured at 2 months and strength changes at 4 months. Nothing meaningful should be expected before 8 weeks, and a fair individual assessment requires 4 months.
Common pitfalls: Buying an unverified product and concluding the compound does not work. Expecting reliable performance gains while already well trained, when the trained-athlete data is split between a null performance result in distance runners and a positive one in a small soccer pilot. Substituting it for resistance training rather than adding it to training. Taking it fasted, which reduces absorption of a lipophilic compound and increases gastrointestinal symptoms. Confusing pomegranate extract with urolithin A. Stacking it simultaneously with several other anti-inflammatory supplements, which makes any biomarker change uninterpretable. Stopping at 6 weeks because nothing has happened.
Regulatory status: In the United States it is a dietary supplement, with a Generally Recognized as Safe notification for the branded ingredient in specified food categories; the Food and Drug Administration does not assess efficacy for supplements. In the European Union it is an authorized novel food for adults in food supplements, with a daily limit for the branded ingredient. It is not a medicine anywhere and is not approved to treat any condition. Advertising claims have been constrained: in 2025 the leading manufacturer agreed to modify muscle-benefit claims following a U.S. advertising self-regulatory challenge.
Cost and accessibility: This is an exceptionally expensive supplement. Trial-equivalent dosing of a verified branded product costs roughly USD 1.50–3.00 per day, or approximately USD 550–1,100 per year, indefinitely. No insurer or national health system reimburses it, and because no institutional payer stands to gain or lose from its use, there is no structural funder for independent efficacy trials — a gap that leaves the manufacturer as the principal source of evidence about its own product. Availability is straightforward online and through supplement retailers in most markets, but verified product is meaningfully more expensive and less widely stocked than unverified product.
Measurement access: Plasma or dried-blood-spot urolithin A testing is not offered by routine clinical laboratories and requires a specialty or research program, which limits how easily an individual can confirm exposure.

Interaction with Foundational Habits

Sleep: No direct interaction has been documented — urolithin A is not stimulating or sedating, and no trial reported sleep disturbance. The plausible indirect route runs through inflammation, since lowering inflammatory signalling can improve sleep continuity, but this has not been measured. Practical consideration: a trial combining urolithin A with fisetin and measuring sleep quality and aging biomarkers began recruiting in 2025, so a direct answer is pending. Until then, evening dosing has no sleep-related advantage or disadvantage, and protocols simply place the dose with whichever meal best supports absorption.
Nutrition: Direct and potentiating in one respect, redundant in another. Taking the dose with 10–15 g of fat meaningfully improves absorption of a lipophilic, poorly water-soluble compound, so a fat-containing meal is a genuine potentiator. Conversely, a diet already rich in ellagitannins — pomegranate, walnuts, pecans, strawberries, raspberries — supplies precursors, but this only matters for the roughly 40% of people whose microbiome can convert them, and even then produces more than six-fold lower exposure than direct supplementation. Urolithin A does not deplete any known nutrient. Practical consideration: a high-fiber, plant-diverse diet supports the gut bacteria that make urolithins from food, which is worthwhile independently but does not substitute for the supplement in a non-producer.
Exercise: Direct and overlapping, with an unresolved question about whether the overlap is additive or competitive. Resistance and endurance training are themselves powerful inducers of mitophagy, mitochondrial biogenesis and reduced inflammation — the same endpoints urolithin A moves. In untrained people the two appear complementary, since strength and endurance gains occurred without any structured training. In trained athletes, urolithin A reduced markers of muscle damage and perceived exertion without improving performance, which is consistent either with a recovery benefit or with a mild blunting of the inflammatory stress that drives adaptation. Practical consideration: because a plausible blunting mechanism exists but has not been demonstrated, and because muscle-damage markers fell, athletes in a heavy adaptation block may prefer to schedule use during recovery and taper phases rather than during peak overload.
Stress management: No direct interaction with cortisol or the stress response has been measured in any human trial. The plausible indirect route is that chronic psychological stress raises inflammatory signalling and impairs mitochondrial function, so the compound and stress management act on a shared downstream target rather than on each other. Practical consideration: elevated CRP driven by unmanaged stress, poor sleep or visceral adiposity will not be corrected by a supplement acting at the margin, and interpreting an unchanged inflammation marker as non-response is a mistake if those upstream drivers are untreated.

Monitoring Protocol & Defining Success

Before starting, a baseline set of measurements serves two purposes: it establishes whether liver and kidney function are normal, since trial safety data comes exclusively from people with normal organ function, and it captures the inflammation and metabolic markers that the compound has been shown to move. Without a baseline there is no way to distinguish response from noise, which matters more than usual here because the effects are modest and the cost is high.

Ongoing monitoring in published protocols follows a defined cadence: the full panel is repeated at 3 months, again at 6 months, and then every 6–12 months during continued use. Functional testing — grip strength, a repeatable endurance test, and a timed walk or step test — is performed at baseline, 2 months, and 4 months, since that is the window in which functional changes appeared in the trials.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
hs-CRP	<0.5 mg/L	Tracks the low-grade inflammation this compound most consistently lowers	High-sensitivity C-reactive protein, a general marker of body-wide inflammation. Fasting not required. Conventional laboratories treat anything under 3.0 mg/L as low risk, a much looser bar than the functional target. Repeat if any infection occurred within 2 weeks
IL-6	<1.5 pg/mL	A second, independent inflammation signal that complements hs-CRP	Interleukin-6, an inflammatory messenger protein. Draw in the morning; levels rise sharply after hard exercise, so avoid sampling within 48 hours of heavy training
ALT and AST	ALT 10–19 U/L (women), 10–26 U/L (men); AST 10–26 U/L	Confirms normal liver handling of a heavily liver-conjugated compound	Alanine aminotransferase and aspartate aminotransferase, two liver enzymes. Conventional upper limits of roughly 35–55 U/L are far looser than the functional range. Pair with GGT (gamma-glutamyl transferase, an enzyme reflecting bile-duct stress and oxidative load)
eGFR with serum creatinine	eGFR >90 mL/min/1.73 m²	Conjugated urolithin A is cleared by the kidneys	Estimated glomerular filtration rate, a calculated measure of kidney filtering speed. Conventional laboratories flag only values below 60 mL/min/1.73 m², a much looser bar than the functional target. Avoid creatine supplements and hard exercise for 48 hours beforehand, since both raise creatinine. Cystatin C, an alternative filtration marker unaffected by muscle mass, is a useful cross-check in muscular people
Fasting insulin	2–5 µIU/mL	Sets the metabolic context in which a mitochondrial intervention is being judged	Conventional reference ranges extend to roughly 25 µIU/mL, far above the functional target. Requires an 8–12 hour fast. Pair with fasting glucose to calculate HOMA-IR (homeostatic model assessment of insulin resistance, a simple index derived from the two values)
HbA1c	4.8–5.3%	A slower-moving metabolic anchor that will not be confounded by a single day	Glycated hemoglobin, roughly a three-month average of blood sugar. Reads falsely low with anemia or a shortened red-blood-cell lifespan. Conventional “normal” extends to 5.6%
Lipid panel with ApoB	ApoB <80 mg/dL; HDL-C >50 mg/dL (women), >45 mg/dL (men)	The one cardiovascular signal reported in a trial was a lipid shift, so lipids anchor a plausible change	ApoB is apolipoprotein B, a count of cholesterol-carrying particles and a better risk marker than total cholesterol; HDL-C is high-density lipoprotein cholesterol. Conventional laboratories treat ApoB up to roughly 90–130 mg/dL as acceptable, well above the functional target. Non-fasting sampling is acceptable for ApoB
Creatine kinase	40–200 U/L	Recovery marker, most useful for anyone training hard	An enzyme released when muscle fibers are damaged. Stays elevated for up to 7 days after unaccustomed or downhill work, so interpret only against a known recent training load
Plasma urolithin A glucuronide	Detectable, ideally >1 µmol/L at 6 hours post-dose	The only direct proof that the product contains the compound and that it is being absorbed	The conjugated form that dominates in blood; free urolithin A is barely measurable. Requires a specialty or research laboratory or a dried-blood-spot program. Given the documented rate of underdosed and counterfeit product, this is the highest-value single measurement available

Qualitative markers to track alongside the laboratory panel:

Perceived exertion during a familiar training session at a fixed workload — the most consistently reported subjective change in trial participants
Recovery time and severity of delayed-onset muscle soreness after hard or unaccustomed sessions
Ease of everyday sustained tasks such as stair climbing, carrying, or long walks, which reflects endurance rather than peak strength
Energy stability across the afternoon, without the artificial lift of a stimulant
Sleep continuity and morning restedness, as a check that nothing has worsened
Subjective cognitive clarity, recorded honestly as an unvalidated marker given the absence of human cognitive data

Defining success: a reasonable individual threshold at 4 months is a measurable fall in hs-CRP, a measurable improvement in a repeatable endurance test, and no adverse change in liver or kidney markers. Absence of movement in both the inflammation marker and the functional test, in someone with confirmed absorption, is a reasonable basis to conclude non-response.

Emerging Research

The next three years should substantially change what can be said about urolithin A, because for the first time a majority of active trials are being run by academic institutions and government agencies rather than by the ingredient manufacturer. Both directions of evidence are represented below — trials that could strengthen the case and trials that could weaken it.

Cognitive function in aging adults: NCT07060898 is testing a brain-focused supplement containing urolithin A on cognitive function, brain fog and related outcomes in 650 participants. It is the largest urolithin A study ever run and the first to make cognition a primary endpoint, but it is sponsored by Amazentis SA and tests a multi-ingredient product, which will limit attribution to urolithin A specifically.
Independent glucose metabolism trial: NCT06274749, sponsored by the U.S. National Institute on Aging, is a randomized triple-masked trial of urolithin A supplementation on glucose metabolism in 180 healthy adults aged 55 and over. Government sponsorship removes the manufacturer-funding objection, and a null result in a trial this size would meaningfully weaken the metabolic-benefit case.
Prostate cancer surgical window trial: NCT06022822, the URO-PRO trial sponsored by the U.S. National Cancer Institute, is a Phase 2 placebo-controlled study in 90 men with prostate adenocarcinoma undergoing radical prostatectomy. Because tissue is removed at surgery, it can directly measure what urolithin A does inside a human tumor — the first study capable of testing whether the effect is protective or, as context-dependent mitophagy models predict, potentially permissive.
Cancer immunotherapy combination: NCT07161310, run by Goethe University in 45 patients with previously untreated solid tumors receiving immune checkpoint inhibitors, follows directly from the T cell findings of Denk et al., 2025. This is the highest-risk, highest-information trial in the field: it could establish a genuine therapeutic role or reveal an interaction that argues against use in anyone with cancer.
Brain exposure and blood-brain barrier penetration: NCT07517913, sponsored by Amazentis SA, will measure cerebrospinal fluid kinetics of urolithin A in 40 healthy adults. This is the prerequisite study for every neurological claim, and a negative result — showing that little reaches the central nervous system — would undercut the entire brain-health rationale reviewed by Zhang et al., 2025.
Replication of the core muscle finding: NCT07231783, registered as ATLAS 2 and sponsored by Amazentis SA, is a 120-participant trial of urolithin A on muscle strength in healthy middle-aged adults, with primary completion expected in late 2027. Since the 12% strength gain is the single most cited number about this compound and came from a trial that missed its own primary endpoint, a well-powered replication is the most consequential pending result for the strength claim — though it is an internal replication by the same sponsor as the original, not an independent one.
Muscle disuse and frailty: NCT05814705 at McMaster University is testing protein supplementation with or without urolithin A during single-leg immobilization in 24 participants, an efficient model for whether the compound protects muscle during forced inactivity. A separate manufacturer-run study in frail older adults, NCT06556706, completed in 2025 and examined mitochondrial quality in muscle in the population with the most to gain.
Sleep and aging biomarkers: NCT06990256, run by Huazhong University of Science and Technology in 80 participants, is evaluating urolithin A together with fisetin on sleep and aging biomarkers. It will provide the first controlled data on an interaction that is currently entirely unmeasured.
Precision geroscience frameworks: The PROMETHEUS protocol, NCT07451496 from the National University of Singapore and described in Kuerec et al., 2026, places urolithin A within a personalised combination of lifestyle measures and nutraceuticals rather than testing it alone. This design reflects a broader shift away from single-compound longevity trials and will make attribution harder even as it improves realism.
Areas of future research that could change current understanding: Four questions are open and consequential. First, whether the biochemical signature translates into any hard outcome, since no trial has measured falls, fractures, infections, hospitalisation or mortality. Second, whether mitophagy is genuinely the mechanism, given that mitochondrial capacity did not improve in the trials that measured it — the alternative anti-inflammatory account reviewed by García-Villalba et al., 2022 has not been ruled out. Third, whether long-term mitophagy induction is safe in people carrying occult tumors, a concern raised directly by the context-dependent framing in Wu et al., 2026. Fourth, whether the compound adds anything on top of resistance training, which no trial has yet tested head to head.

Conclusion

Urolithin A is a compound made by gut bacteria from substances in pomegranates, walnuts and berries, now sold in purified form because most people make little of it from food. Its appeal rests on a single idea: helping cells retire damaged energy factories and build new ones, a process that falters with age.

The human record is young but not empty. Across several placebo-controlled studies in middle-aged and older adults, the most repeatable findings are improved muscle endurance and shifts in blood markers tied to energy handling and low-grade inflammation. Gains in strength are plausible but less consistent, and studies in already-fit athletes have shown better recovery rather than better performance. Signals for the brain, joints and cancer rest on animal and cell work only, and the measures that would confirm the proposed mechanism in people have not moved.

Two features shape how much weight this evidence carries. Most of the human research was funded and co-authored by the company that makes the leading branded ingredient, an arrangement that does not invalidate the findings but is a standard reason for caution. And the market itself is unreliable: independent testing has repeatedly found products containing far less than the label claims, and courts have acted against sellers of counterfeit material.

Safety over months looks unremarkable, with side effects at placebo-like rates and no sign of organ harm. What remains unknown is the effect of years of use, and whether the measured biological changes amount to a longer or healthier life.

Top - Benefits - Risks - Protocol

Urolithin A for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Improved Muscle Endurance

Improved Markers of Mitochondrial and Cellular Health

Medium 🟩 🟩

Increased Muscle Strength ⚠️ Conflicted

Reduced Systemic Inflammation

Remodeling of the Aging Immune System

Faster Recovery from Strenuous Exercise

Low 🟩

Improved Aerobic Capacity ⚠️ Conflicted

Favorable Shift in Blood Lipids ⚠️ Conflicted

Speculative 🟨

Brain and Cognitive Aging

Joint Cartilage Preservation

Cancer Risk Modulation

Lifespan Extension

Metabolic and Glucose Regulation

Skin Aging

Protection of Kidney Function

Retinal and Macular Health

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Mild Gastrointestinal Symptoms

Medium 🟥 🟥

Widespread Product Adulteration and Underdosing

Unknown Safety Beyond Four Months of Continuous Use

Low 🟥

Discordant Inflammatory and Antioxidant Marker Changes ⚠️ Conflicted

Cost Without Demonstrated Hard-Outcome Benefit

Speculative 🟨

Interference with Tumor Biology or Cancer Immunotherapy

Estrogen-Receptor Activity in Hormone-Sensitive Conditions

Immune or Gut-Barrier Effects from Aryl Hydrocarbon Receptor Antagonism

Competition for Phase II Conjugation Capacity

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion